A new startup wants to fight cancer with 'off-the-shelf' gene therapy, securing $26M seed round

Max Gelman

Senior Editor

A new startup attempting to develop AAV gene therapies to treat cancer emerged from stealth Thursday morning with $26 million in seed funding — and a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A new startup wants to fight cancer with 'off-the-shelf' gene therapy, securing $26M seed round

Max Gelman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Bad trip: How culture conflict and a need for cash nearly broke Lykos

After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

Cigna sues FTC, calling for withdrawal of 'biased, erroneous' PBM report

Merck and Daiichi’s rejected HER3 ADC clears a Phase 3 in certain lung cancers

Breaking down silos with a new quantitative approach to drug development

A new start­up wants to fight can­cer with 'off-the-shelf' gene ther­a­py, se­cur­ing $26M seed round

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

A new startup wants to fight cancer with 'off-the-shelf' gene therapy, securing $26M seed round